This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (13)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Macular Degeneration  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Ziad F. Bashshur, MD; Alexandre Schakal, MD; Rola N. Hamam, MD; Christelle P. El Haibi, MS; Rola F. Jaafar, MS; Baha’ N. Noureddin, MD

Arch Ophthalmol. 2007;125(10):1357-1361.

Objective  To compare verteporfin photodynamic therapy (PDT) with intravitreal bevacizumab for management of choroidal neovascularization (CNV) associated with age-related macular degeneration.

Methods  Patients with predominantly classic CNV were prospectively randomized to receive standard PDT or intravitreal bevacizumab injections (2.5 mg). Best-corrected visual acuity (BCVA) measured by Snellen charts, central retinal thickness by optical coherence tomography, and greatest linear dimension of the CNV by fluorescein angiography were compared between the groups at baseline and at 3 and 6 months. Main outcome measures were stability or improvement in BCVA, decrease in central retinal thickness, and stability in greatest linear dimension.

Results  Mean baseline BCVA, central retinal thickness, and greatest linear dimension were not statistically different between the bevacizumab (n = 32) and PDT (n = 30) groups. Mean central retinal thickness was significantly better at 3 and 6 months in the bevacizumab group vs the PDT group (P = .04 and P = .002, respectively). At 3 months, mean BCVA and greatest linear dimension were not significantly different between the 2 groups. At 6 months, mean BCVA and greatest linear dimension were significantly better in the bevacizumab group (P < .001 and P = .02, respectively).

Conclusion  During 6 months, intravitreal bevacizumab was superior to PDT in controlling predominantly classic CNV in age-related macular degeneration. Additional randomized clinical trials are necessary to determine if this benefit will remain with longer follow-up.

Author Affiliations: Department of Ophthalmology, American University of Beirut (Drs Bashshur, Hamam, and Noureddin and Mss El Haibi and Jaafar), and the Department of Ophthalmology, Hotel Dieu de France, St Joseph University (Dr Schakal), Beirut, Lebanon.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Necessity of Paracentesis Before or After Intravitreal Injection of Bevacizumab
Wei-Cheng Huang, Jane-Ming Lin, Chun-Chi Chiang, and Yi-Yu Tsai
Arch Ophthalmol. 2008;126(9):1314-1315.
EXTRACT | FULL TEXT  

Necessity of Paracentesis Before or After Intravitreal Injection of Bevacizumab—Reply
Ziad F. Bashshur
Arch Ophthalmol. 2008;126(9):1315.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Necessity of Paracentesis Before or After Intravitreal Injection of Bevacizumab
Huang et al.
Arch Ophthalmol 2008;126:1314-1315.
FULL TEXT  

Necessity of Paracentesis Before or After Intravitreal Injection of Bevacizumab--Reply
Bashshur
Arch Ophthalmol 2008;126:1315-1315.
FULL TEXT  

Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy
Moreno and Paloma
Br. J. Ophthalmol. 2008;92:866-867.
FULL TEXT